Nuveen LLC Takes $2.32 Million Position in Vir Biotechnology, Inc. $VIR

Nuveen LLC acquired a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 358,575 shares of the company’s stock, valued at approximately $2,324,000. Nuveen LLC owned approximately 0.26% of Vir Biotechnology as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Vir Biotechnology in the fourth quarter worth about $42,000. GAMMA Investing LLC lifted its position in shares of Vir Biotechnology by 524.3% in the first quarter. GAMMA Investing LLC now owns 7,111 shares of the company’s stock worth $46,000 after buying an additional 5,972 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Vir Biotechnology by 26.2% in the first quarter. PNC Financial Services Group Inc. now owns 10,459 shares of the company’s stock worth $68,000 after buying an additional 2,171 shares in the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Vir Biotechnology in the first quarter worth about $78,000. Finally, Nebula Research & Development LLC purchased a new stake in shares of Vir Biotechnology in the fourth quarter worth about $84,000. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Vir Biotechnology

In related news, EVP Mark Eisner sold 6,796 shares of Vir Biotechnology stock in a transaction dated Tuesday, July 15th. The stock was sold at an average price of $5.47, for a total value of $37,174.12. Following the sale, the executive vice president directly owned 108,204 shares in the company, valued at approximately $591,875.88. The trade was a 5.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Vicki L. Sato sold 22,000 shares of the firm’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $4.99, for a total transaction of $109,780.00. Following the completion of the transaction, the director directly owned 1,276,391 shares in the company, valued at $6,369,191.09. This trade represents a 1.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 57,582 shares of company stock worth $294,930 over the last 90 days. Insiders own 16.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Needham & Company LLC restated a “buy” rating and set a $14.00 price objective on shares of Vir Biotechnology in a research report on Thursday, May 22nd. Raymond James Financial assumed coverage on Vir Biotechnology in a research report on Friday, July 11th. They set an “outperform” rating on the stock. Finally, Bank of America upgraded Vir Biotechnology from a “neutral” rating to a “buy” rating and upped their price objective for the company from $12.00 to $14.00 in a research report on Wednesday. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Vir Biotechnology presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.44.

Vir Biotechnology Stock Down 2.0%

Vir Biotechnology stock opened at $4.94 on Friday. The business has a fifty day moving average of $5.09 and a two-hundred day moving average of $5.90. The firm has a market cap of $686.26 million, a P/E ratio of -1.24 and a beta of 1.18. Vir Biotechnology, Inc. has a twelve month low of $4.16 and a twelve month high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.08). The business had revenue of $1.21 million for the quarter, compared to analysts’ expectations of $2.38 million. Vir Biotechnology had a negative net margin of 2,895.94% and a negative return on equity of 50.22%. The business’s revenue for the quarter was down 60.5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.02) EPS. Equities analysts expect that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).